argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
25 aug 2015 - 18:01
Statutaire naam
argenx SE
Titel
arGEN-X ANNOUNCES HALF-YEAR RESULTS FOR 2015
Bericht
Breda, the Netherlands / Ghent, Belgium, August 25 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provided a business update and announced its financial results for the first half of 2015 (six-month period ended June 30, 2015).
Gerelateerde downloads
Datum laatste update: 02 september 2024